Business
CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE
A Safe and Effective Non-Opioid Pain Management SolutionNASHVILLE, Tenn., April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a
About this update from Cumberland Pharmaceuticals Inc.
[{"type":"text","content":"A Safe and Effective Non-Opioid Pain Management SolutionNASHVILLE, Tenn., April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its Caldolor® (ibuprofen) Injection product. The indication now includes the management of postoperative pain, and the approval coincides with the launch of a newly designed website for healthcare professionals highlighting this advancement and the evolving role of non-opioid pain management. \nWith this update, Caldolor is indicated for use in adult and pediatric patients ages 3 months and older for:Management of mild to moderate pain, including postoperative painManagement of moderate to severe pain, including postoperative pain, as an adjunct to opioid analgesicsReduction of feverThis expanded labeling reinforces Caldolor's role as a versatile, non-opioid intravenous analgesic option for use in perioperative and acute care settings.Advancing Perioperative Pain ManagementThe newly launched Caldolor website aligns with this expanded indication, featuring dedicated content on postoperative pain management and the importance of multimodal, opioid-sparing approaches.Postoperative pain remains a significant challenge across surgical setting, with a growing emphasis on reducing opioid exposure while maintaining effective pain control. The updated website provides healthcare professionals with resources that focus on:The role of IV non-opioid options like Caldolor in perioperative careStrategies to support opioid stewardship amid the ongoing opioid crisisClinical data supporting safe and effective pain and fever management with CaldolorIn addition to featuring the new postoperative pain indication, the website offers comprehensive information on safety, dosing, efficacy, and access with J-Code reimbursement support.The site reinforces Caldolor as \"A Safe and Effective Non-Opioid Pain Management Solution.\"Healthcare professionals can explore the updated website and resources at www.caldolor.com, which includes full prescribing and safety information.For medical inquiries, contact [email protected]. For product access support, contact [email protected] Caldolor® (ibuprofen) InjectionCaldolor is indic...